Cerebain Biotech logo

CBBT - Cerebain Biotech Share Price

$0.025 0.0  0.0%

Last Trade - 02/12/20

Sector
Healthcare
Size
Micro Cap
Market Cap £2.60m
Enterprise Value £5.64m
Revenue £n/a
Position in Universe th / 6444
Bullish
Bearish
Unlock CBBT Revenue
Momentum
Relative Strength (%)
1m +31.2%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -34.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2013 2014 2015 2016 2017 2018 2019E 2020E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 31 March 2019, CerebainBiotech Corp revenues was not reported. Net loss decreased71% to $1.3M. Lower net loss reflects Loss fromextinguishment of debt decrease of 100% to $15K (expense),Selling, general and administrative expe decrease of 22% to$616K (expense), Research and development costs decrease of84% to $32K (expense). Basic Earnings per Share excludingExtraordinary Items increased from -$0.54 to -$0.09.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CBBT Revenue Unlock CBBT Revenue

Net Income

CBBT Net Income Unlock CBBT Revenue

Normalised EPS

CBBT Normalised EPS Unlock CBBT Revenue

PE Ratio Range

CBBT PE Ratio Range Unlock CBBT Revenue

Dividend Yield Range

CBBT Dividend Yield Range Unlock CBBT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CBBT EPS Forecasts Unlock CBBT Revenue
Profile Summary

Cerebain Biotech Corp. is a biomedical company. The Company operates as a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device. The Company, through its subsidiary, Cerebain Operating, Inc., is involved in the discovery of products for the treatment of Alzheimer's disease utilizing Omentum. The Omentum is a layer of tissue lying over internal organs (such as the intestines) and has the ability to generate biological agents that nourish nerves and help them grow. The Company is focused on inclusion of both a medical device solution, as well as a synthetic drug solution in its products. The Company is in the process of preparing for initial clinical trials.

Directors
Last Annual June 30th, 2018
Last Interim March 31st, 2019
Incorporated December 18, 2007
Public Since September 20, 2011
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Pink Sheets on Nasdaq
Shares in Issue 140,223,096
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CBBT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CBBT
Upcoming Events for CBBT
Frequently Asked Questions for Cerebain Biotech
What is the Cerebain Biotech share price?

As of 02/12/20, shares in Cerebain Biotech are trading at $0.025, giving the company a market capitalisation of £2.60m. This share price information is delayed by 15 minutes.

How has the Cerebain Biotech share price performed this year?

Shares in Cerebain Biotech are currently trading at $0.025 and the price has moved by 2.99k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cerebain Biotech price has moved by 2.60k% over the past year.

What are the analyst and broker recommendations for Cerebain Biotech?

There are no analysts currently covering Cerebain Biotech.

When will Cerebain Biotech next release its financial results?

Cerebain Biotech is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-03-31
What is the Cerebain Biotech dividend yield?

Cerebain Biotech does not currently pay a dividend.

Does Cerebain Biotech pay a dividend?

Cerebain Biotech does not currently pay a dividend.

When does Cerebain Biotech next pay dividends?

Cerebain Biotech does not currently pay a dividend.

How do I buy Cerebain Biotech shares?

To buy shares in Cerebain Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Cerebain Biotech?

Shares in Cerebain Biotech are currently trading at $0.025, giving the company a market capitalisation of £2.60m.

Where are Cerebain Biotech shares listed? Where are Cerebain Biotech shares listed?

Here are the trading details for Cerebain Biotech:

Country of listing: United States
Exchange: PNK
Ticker Symbol: CBBT
What kind of share is Cerebain Biotech?

We were not able to load our ranking data for Cerebain Biotech

Is there a Cerebain Biotech share price forecast 2020?

We were not able to load any forecast data for Cerebain Biotech.

How can I tell whether the Cerebain Biotech share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cerebain Biotech. Over the past six months, the relative strength of its shares against the market has been 2.97k%. At the current price of $0.025, shares in Cerebain Biotech are trading at 0.515k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Cerebain Biotech PE Ratio?

We were not able to find PE ratio data for Cerebain Biotech.

Who are the key directors of Cerebain Biotech?

Cerebain Biotech's management team is headed by:

Eric Clemons - PRE
Who are the major shareholders of Cerebain Biotech?

Here are the top five shareholders of Cerebain Biotech based on the size of their shareholding:

Clemons (Eric) Individual Investor
Percentage owned: 0.87% (1.22m shares)
Tate (Wesley D) Individual Investor
Percentage owned: 0.56% (782k shares)
Similar to CBBT
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.